Innate Pharma highlights preclinical anti-tumor efficacy data of its antibody drug conjugate IPH4502 at the AACR 2025 annual meeting

CAR-T Digest - August 2020

29 Apr 2025: Innate Pharma highlights preclinical anti-tumor efficacy data of its antibody drug conjugate IPH4502 at the AACR 2025 annual meeting

Innate Pharma presented new preclinical data at AACR 2025 showing that its ADC IPH4502, targeting Nectin-4, demonstrated superior anti-tumor activity compared to Enfortumab vedotin in models with low or resistant Nectin-4 expression
IPH4502 outperformed existing therapies in urothelial carcinoma models, including those resistant to Enfortumab vedotin due to multi-drug resistance mechanisms
The ADC showed strong preclinical efficacy in additional tumor types such as triple-negative breast cancer, head and neck, and esophageal cancers, supporting broader clinical potential
IPH4502 leverages a topoisomerase I inhibitor payload, offering improved internalization, cytotoxicity, and bystander killing effect compared to other Nectin-4-exatecan ADCs
The data supports IPH4502 as a differentiated ADC candidate with potential to overcome resistance and toxicity limitations of current Nectin-4-targeting therapies